Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Generally mild injection-site reactions, flushing, headache, water retention
They are complementary rather than competing, with BPC-157 addressing structural repair and LL-37 addressing infection defense and innate immune signaling during wound healing
However, peptides with little clinical research were on the chopping block due to concerns of impurities and dangerous side effects linked to compounded treatments
Through its effects on cytoskeletal organization and blood flow, TB-500 is studied for its potential role in supporting recovery processes related to tendon injuries, ligaments, and other connective tissues under controlled research conditions
How it works: GHRH receptor agonism (CJC-1295): binds pituitary somatotrophs via the GHRH receptor, amplifying baseline GH pulse amplitude and duration over the course of days due to albumin binding Ghrelin receptor agonism (Ipamorelin): activates GHS-R1a with an earlier onset and more immediate GH secretion spike compared to GHRH analogs, providing a complementary time profile Sequential synergy: the two peptides act on distinct receptor systems and exhibit a combined GH output greater than either alone, with ipamorelin providing the acute peak and CJC-1295 sustaining elevated trough levels IGF-1 elevation: downstream GH signaling raises circulating IGF-1, the primary mediator of tissue repair, protein synthesis, and connective tissue remodeling
US$ 24.08
US$ 28.03
US$ 24.39
US$ 28.45
